Legend Biotech Corp Cash Flows From Used In Financing Activities
Legend Biotech Corp (LEGN) reported Cash Flows From Used In Financing Activities of -$300.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Cash Flow › Financing Activities
ifrs-full:CashFlowsFromUsedInFinancingActivities · last filed 2026-03-10
- Legend Biotech Corp cash flows from used in financing activities for the quarter ending 2025-12-31 was -$647.00K.
- Legend Biotech Corp cash flows from used in financing activities for the quarter ending 2025-09-30 was $670.00K, a 84.22% decline year-over-year.
- Legend Biotech Corp cash flows from used in financing activities for the quarter ending 2025-06-30 was -$990.00K, a 203.66% decline year-over-year.
- Legend Biotech Corp cash flows from used in financing activities for the quarter ending 2025-03-31 was $667.00K, a 19.74% decline year-over-year.
| Period end | Cash Flows From Used In Financing Activities 3 month | Cash Flows From Used In Financing Activities 6 month | Cash Flows From Used In Financing Activities 9 month | Cash Flows From Used In Financing Activities 12 month | Cash Flows From Used In Financing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$647.00K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $23.00K derived: sum of 2 quarters · filed 2026-03-10 | -$967.00K derived: sum of 3 quarters · filed 2026-03-10 | -$300.00K 20-F · filed 2026-03-10 | |
| 2025-09-30 | $670.00K derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | -$320.00K derived: sum of 2 quarters · filed 2025-11-12 | $347.00K 6-K · filed 2025-11-12 | $16.00K derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-06-30 | -$990.00K derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | -$323.00K 6-K · filed 2025-08-11 | -$654.00K derived: sum of 3 quarters · filed 2026-03-10 | $3.59M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | $667.00K 6-K · filed 2025-05-13 | $336.00K derived: sum of 2 quarters · filed 2026-03-10 | $4.58M derived: sum of 3 quarters · filed 2026-03-10 | $5.54M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | -$331.00K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $3.91M derived: sum of 2 quarters · filed 2026-03-10 | $4.87M derived: sum of 3 quarters · filed 2026-03-10 | $5.70M 20-F · filed 2026-03-10 | $5.70M 20-F · filed 2025-03-11 |
| 2024-09-30 | $4.25M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $5.20M derived: sum of 2 quarters · filed 2025-11-12 | $6.03M 6-K · filed 2025-11-12 | $6.87M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-06-30 | $955.00K derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | $1.79M 6-K · filed 2025-08-11 | $2.62M derived: sum of 3 quarters · filed 2026-03-10 | $3.58M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-03-31 | $831.00K 6-K · filed 2025-05-13 | $1.67M derived: sum of 2 quarters · filed 2026-03-10 | $2.63M derived: sum of 3 quarters · filed 2026-03-10 | $792.67M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2023-12-31 | $835.00K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $1.80M derived: sum of 2 quarters · filed 2026-03-10 | $791.84M derived: sum of 3 quarters · filed 2026-03-10 | $791.40M 20-F · filed 2026-03-10 | $791.49M 20-F · filed 2024-03-19 |
| 2023-09-30 | $961.00K derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $791.01M derived: sum of 2 quarters · filed 2024-11-12 | $790.57M 6-K · filed 2024-11-12 | $789.78M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | $790.05M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $789.60M 6-K · filed 2024-08-09 | $788.82M derived: sum of 3 quarters · filed 2025-03-11 | $1.17B derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | -$444.00K 6-K · filed 2024-05-13 | -$1.23M derived: sum of 2 quarters · filed 2025-03-11 | $376.50M derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | -$783.00K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $376.94M derived: sum of 2 quarters · filed 2025-03-11 | $377.98M 20-F · filed 2025-03-11 | ||
| 2022-09-30 | $377.73M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $378.76M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | $1.03M 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | $626.66M 20-F · filed 2024-03-19 | ||||
| 2021-06-30 | $301.96M 6-K · filed 2021-08-23 | ||||
| 2020-12-31 | $618.88M 20-F · filed 2023-03-30 | ||||
| 2020-06-30 | $608.56M 6-K · filed 2021-08-23 | ||||
| 2019-12-31 | $14.67M 20-F/A · filed 2023-02-17 | ||||
| 2018-12-31 | $2.50M 20-F · filed 2021-04-02 |